Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771218 | 0.94 | NR1H4 (0.51) | NR1H4MAPK14MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL2770584 | 0.92 | NR1H4 (0.54) | NR1H4MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL2773939 | 0.90 | NR1H4 (0.52) | NR1H4MRGPRX4 | |
| SCHEMBL2771523 | 0.90 | NR1H4 (0.51) | NR1H4TRPM8 | |
| SCHEMBL2770441 | 0.89 | NR1H4 (0.54) | NR1H4MRGPRX4 | |
| SCHEMBL2773103 | 0.89 | NR1H4 (0.52) | NR1H4MRGPRX4CYP4F2CYP4A11PTPN1 | |
| SCHEMBL2771518 | 0.88 | NR1H4 (0.50) | NR1H4MAPK14MRGPRX4 | |
| SCHEMBL2773707 | 0.88 | NR1H4 (0.60) | NR1H4MRGPRX4TRPM8 | |
| SCHEMBL2770617 | 0.88 | NR1H4 (0.51) | NR1H4MAPK14MRGPRX4 | |
| SCHEMBL2771344 | 0.88 | NR1H4 (0.51) | NR1H4MAPK14MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | claimed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | claimed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | claimed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885MAPK14 2903/4885MRGPRX4 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.